Minerva Neurosciences (NASDAQ:NERV) Downgraded to Sell at StockNews.com

Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Separately, HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday, May 2nd.

Minerva Neurosciences Price Performance

Shares of Minerva Neurosciences stock opened at $2.51 on Friday. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49. The firm has a market capitalization of $17.55 million, a PE ratio of -0.56 and a beta of 0.27. The stock’s fifty day moving average is $2.56 and its 200-day moving average is $5.22.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. Analysts expect that Minerva Neurosciences will post -1.89 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.